GlassScriptPhysician profile
Lance W Weathers
NPI 1902086119
$7,700.43
in general payments reported to CMS, 2019-2025
41 companies · $815 in 2025
The $815 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,534 · 2020: $1,206 · 2021: $1,256 · 2022: $903 · 2023: $970 · 2024: $1,016 · 2025: $815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,800.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,046.38 | 2019-2025 | Esprit, Xience Skypoint, Amplatzer Amulet |
| Novartis Pharmaceuticals Corporation | $667.59 | 2019-2025 | |
| Medtronic, INC. | $523.87 | 2021-2024 | Corevalve Evolut R, Micra, Linq II |
| Pfizer INC. | $521.16 | 2019-2025 | |
| Amgen INC. | $456.98 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $424.49 | 2019-2024 | Xarelto |
| Edwards Lifesciences Corporation | $424.05 | 2019-2025 | Sapien 3 Ultra Resilia |
| Heartflow, INC. | $239.23 | 2020-2022 | |
| Medtronic Vascular, INC. | $236.47 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $221.89 | 2021-2025 | Verquvo |
| Boston Scientific Corporation | $213.06 | 2022-2025 | Ranger, Synergy, Watchman Flx |
| Amarin Pharma, INC. | $166.19 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.07 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $161.03 | 2019-2023 | Farxiga |
| Philips North America LLC | $112.86 | 2019 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $112.35 | 2023-2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.47 | 2019-2020 | |
| Inari Medical, INC. | $82.61 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Bayer Healthcare Pharmaceuticals INC. | $79.40 | 2021-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $75.78 | 2021-2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $73.59 | 2019 | |
| Novo Nordisk INC | $63.47 | 2023 | Ozempic, Rybelsus |
| Regeneron Healthcare Solutions, INC. | $54.05 | 2019 | |
| Cordis US Corp. | $47.96 | 2022-2023 | Mynx Control |
| Esperion Therapeutics, INC. | $44.54 | 2021-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $42.38 | 2021-2024 | Eliquis, Camzyos |
| Scpharmaceuticals INC. | $41.42 | 2023 | |
| Baxter Healthcare | $40.99 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Biosense Webster, INC. | $31.83 | 2025 | Nuvision Ice Catheter, Carto 3 |
| Atricure, INC. | $31.05 | 2019 | |
| Cathworks, INC. | $31.02 | 2025 | Ffrangio |
| Alnylam Pharmaceuticals INC. | $24.13 | 2019 | |
| Biotronik INC. | $23.72 | 2019 | |
| Bard Peripheral Vascular, INC. | $20.46 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $17.67 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $16.86 | 2025 | Attruby |
| Bardy Diagnostics, INC. | $15.00 | 2020 | |
| Genzyme Corporation | $13.96 | 2021 | |
| Cardiva Medical, INC. | $12.03 | 2022 | |
| Gilead Sciences, INC. | $11.99 | 2019 | |
| Chiesi USA, INC. | $11.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Weathers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.